European Society for Radiotherapy and Oncology

Tweet this page
<
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 14 Sep 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

75,000€

Financial year: Jan 2020 - Dec 2020

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    European Society for Radiotherapy and Oncology   (ESTRO)

    EU Transparency Register

    114144232470-50 First registered on 21 Sep 2018

    Goals / Remit

    ESTRO, the European SocieTy for Radiotherapy & Oncology, is a scientific non-profit organisation whose mission is to further reinforce radiation oncology as a core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiation therapy for all cancer patients who need it. This is emphasized in ESTRO’s vision statement for 2030 ‘Radiation Oncology. Optimal Health for All, Together’.

    ESTRO promotes education, science, research and advocate for access to radiotherapy. Throughout the year, the Society organises an annual Congress, teaching courses, workshops, and public affairs activities and publishes scientific material in its family of journals.

    The Society counts over 7,000 members in and outside Europe and supports all the radiation oncology professionals and the wider oncology community in their daily practice.

    https://www.estro.org/ESTRO/media/ESTRO/About/190417-ESTRO-Vision-Paper-2030.pdf

    Main EU files targeted

    EU public health policy, Research and Innovation, Data Protection

    • Europe's Beating Cancer Plan
    • CANCON www.cancercontrol.eu
    • IPAAC Innovative Partnership for Actions Against Cancer https://www.ipaac.eu
    • JARC Joint Action on Cancer (together with SIOPE https://www.siope.eu/)
    • ERN European Reference Network http://www.ern-rnd.eu/
    • IMI Innovative Medicines Agency https://www.imi.europa.eu/
    • COUNCIL DIRECTIVE 2013/59/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/ ARTICLE 63 + 78
    • Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross-border healthcare
    • Directive 2013/35/EU of the European Parliament and of the Council of 26 June 2013 on the minimum health and safety requirements regarding the exposure of workers to the risks arising from physical agents (electromagnetic fields)
    • Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU
    • Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC
    • Inputs provided on the ESCO forum, regarding the professions working in radiotherapy
    • Proposal for a thematic network on EU Health Policy Platform

    Address

    Head Office
    Rue Martin V. 40
    Brussels 1200
    BELGIUM
  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%1
    25%1

    Lobbyists (Full time equivalent)

    0.75

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    European Cancer Organisation
    Union for International Cancer Control (UICC)

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2020 - Dec 2020

    Lobbying costs for closed financial year

    75,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    Projects:
    - HERO project, Health Economics in Radiation Oncology. https://www.estro.org/about-us/health-economics-in-radiation-oncology---hero/hero
    - ROSEIS, Radiation Oncology Safety Education and Information System. https://roseis.estro.org

    Communications activities:
    - ESTRO Annual report 2019 https://user-swndwmf.cld.bz/ESTRO-Annual-Report-2019
    - ESTRO SYMPOSIUM AT THE EUROPEAN PARLAMENT: "Radiotherapy Cures Cancer Today", organised on the 5th Dec 2017. https://www.estro.org/binaries/content/assets/estro/about/news/event-report-radiotherapy-cures-cancer-today-5th-december-2017.pdf

    Publications:
    - Kazmierska J, Jornet Sala N, Leech M, et al. 2019. Radiotherapy: seizing the opportunity in cancer care. Tumori Journal 2019, Vol. 105(2S) 3–59
    - Training Requirements in Radiation Oncology https://www.uems.eu/__data/assets/pdf_file/0015/44430/UEMS-2013.20-European-Training-Requirements-in-Radiation-Oncology.pdf
    - Lievens Y, Defourny N, Coffey M, et al. Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol 2014;112:178– 86
    - Dunscombe P, Grau C, Defourny N, et al. Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey., Radiother Oncol. 2014 Aug;112(2):165-77
    - Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015 Jul;116(1):38-44
    - Borras, J. M., Lievens, Y., Barton, M., et al. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 119(1), 5-11.
    - Defourny, N., Dunscombe, P., Perrier, L., et al. Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. Radiotherapy and Oncology 2016, 121(3), 468-474.
    -Lievens, Yolande; Gospodarowicz, Mary; Grover, Surbhi; Jaffray, David; Rodin, Danielle; Torode, Julie; Yap, Mei Ling; Zubizarreta, Eduardo; GIRO Steering and Advisory Committees - Global impact of radiotherapy in oncology: Saving one million lives by 2035, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 125, Issue: 2, Page: 175-177 Publication Year: 2017
    -Coffey M, Technical Innovations & Patient Support in Radiation Oncology. Elsevier BV ISSN: 2405-6324, Vol: 1, Page: 16-17 Publication Year: 2017
    - Borras, Josep M; Grau, Cai; Corral, Julieta; Wong, Karen; Barton, Michael B; Ferlay, Jacques; Bray, Freddie; Lievens, Yolande, Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, ISSN: 1879-0887, Vol: 126, Issue: 2, Page: 198-204 Publication Year: 2018
    - Lievens Y, Audisio R, Banks I, Collette L, Grau C, Oliver K, Price R, Aggarwal A. Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. Lancet Oncol. 2019;20(2):e112-23.
    - Defourny N, Perrier L, Borras JM, Coffey M, Corral J, Hoozée S, Loon JV, Grau C, Lievens Y. National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. Radiother Oncol. 2019;138:187-94.
    - Defourny N, Monten C, Grau C, Lievens Y, Perrier L. Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data? Radiother Oncol. 2019 Dec;141:14-26.
    - Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM; ESTRO–HERO Consortium Collaborators. How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol. 2020 Jan;21(1):e42-e54

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard